R(+)-methanandamide induces cyclooxygenase-2 expression in human neuroglioma cells via a non-cannabinoid receptor-mediated mechanism

Biochem Biophys Res Commun. 2001 Sep 7;286(5):1144-52. doi: 10.1006/bbrc.2001.5518.

Abstract

Cannabinoids affect prostaglandin (PG) formation in the central nervous system through as yet unidentified mechanisms. Using H4 human neuroglioma cells, the present study investigates the effect of R(+)-methanandamide (metabolically stable analogue of the endocannabinoid anandamide) on the expression of the cyclooxygenase-2 (COX-2) enzyme. Incubation of cells with R(+)-methanandamide was accompanied by concentration-dependent increases in COX-2 mRNA, COX-2 protein, and COX-2-dependent PGE(2) synthesis. Moreover, treatment of cells with R(+)-methanandamide in the presence of interleukin-1beta led to an overadditive induction of COX-2 expression. The stimulatory effect of R(+)-methanandamide on COX-2 expression was mimicked by the structurally unrelated cannabinoid Delta(9)-tetrahydrocannabinol. Stimulation of both COX-2 mRNA expression and subsequent PGE(2) synthesis by R(+)-methanandamide was not affected by the selective CB(1) receptor antagonist AM-251 or the G(i/o) protein inactivator pertussis toxin. Enhancement of COX-2 expression by R(+)-methanandamide was paralleled by time-dependent phosphorylations of p38 mitogen-activated protein kinase (MAPK) and p42/44 MAPK. Consistent with the activation of both kinases, R(+)-methanandamide-induced COX-2 mRNA expression and PGE(2) formation were abrogated in the presence of specific inhibitors of p38 MAPK (SB203580) and p42/44 MAPK activation (PD98059). Together, our results demonstrate that R(+)-methanandamide induces COX-2 expression in human neuroglioma cells via a cannabinoid receptor-independent mechanism involving activation of the MAPK pathway. In conclusion, induction of COX-2 expression may represent a novel mechanism by which cannabinoids mediate PG-dependent effects within the central nervous system.

MeSH terms

  • Analgesics, Non-Narcotic / pharmacology
  • Arachidonic Acids / pharmacology*
  • Blotting, Western
  • Brain Neoplasms / enzymology*
  • Cannabinoid Receptor Modulators
  • Cell Line
  • Central Nervous System / metabolism
  • Cyclooxygenase 2
  • Dinoprostone / metabolism
  • Dose-Response Relationship, Drug
  • Dronabinol / pharmacology
  • Enzyme Activation
  • Enzyme Inhibitors / pharmacology
  • Flavonoids / pharmacology
  • Glioma / enzymology*
  • Humans
  • Imidazoles / pharmacology
  • Interleukin-1 / metabolism
  • Isoenzymes / biosynthesis*
  • Membrane Proteins
  • Mitogen-Activated Protein Kinase 1 / metabolism
  • Mitogen-Activated Protein Kinase 3
  • Mitogen-Activated Protein Kinases / metabolism
  • Pertussis Toxin
  • Phosphorylation
  • Piperidines / pharmacology*
  • Prostaglandin-Endoperoxide Synthases / biosynthesis*
  • Pyrazoles / pharmacology*
  • Pyridines / pharmacology
  • RNA, Messenger / metabolism
  • Receptors, Cannabinoid
  • Receptors, Drug / metabolism
  • Reverse Transcriptase Polymerase Chain Reaction
  • Time Factors
  • Tumor Cells, Cultured
  • Virulence Factors, Bordetella / pharmacology
  • p38 Mitogen-Activated Protein Kinases

Substances

  • Analgesics, Non-Narcotic
  • Arachidonic Acids
  • Cannabinoid Receptor Modulators
  • Enzyme Inhibitors
  • Flavonoids
  • Imidazoles
  • Interleukin-1
  • Isoenzymes
  • Membrane Proteins
  • Piperidines
  • Pyrazoles
  • Pyridines
  • RNA, Messenger
  • Receptors, Cannabinoid
  • Receptors, Drug
  • Virulence Factors, Bordetella
  • methanandamide
  • AM 251
  • Dronabinol
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • Prostaglandin-Endoperoxide Synthases
  • Pertussis Toxin
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • Mitogen-Activated Protein Kinases
  • p38 Mitogen-Activated Protein Kinases
  • Dinoprostone
  • SB 203580
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one